Xeomin® (incobotulinumtoxinA) – Expanded indication
August 19, 2020 - Merz announced the FDA approval of Xeomin (incobotulinumtoxinA), for the treatment or improvement of upper limb spasticity in pediatric patients 2 to 17 years of age, excluding spasticity caused by cerebral palsy.
Download PDF
